title: MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
abstract: MicroRNAs (miRNAs) have been demonstrated to have critical roles in regulating cancer cell proliferation, survival and sensitivity to chemotherapy. The potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms have not been completely understood. Here, we show a strong correlation between miR-621 expression and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients. High level of miR-621 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who also tend to achieve pathological complete response. Ectopic overexpression of miR-621 promoted apoptosis and increased chemosensitivity to PTX and CBP both in cultured breast cancer cells and in xenograft tumor model. We further show that FBXO11 is a direct functional target of miR-621 and miR-621 level is negatively correlated with FBXO11 expression in breast cancer patients. Ectopic expression of FBXO11 attenuated increased apoptosis in breast cancer cells overexpressing miR-621 upon PTX or CBP treatment. Consistently, high FBXO11 expression significantly correlated with poor survival in breast cancer patients. Mechanistically, we found in breast cancer cells FBXO11 interacts with p53 and promotes its neddylation, which suppressed the p53 transactivity. Accordingly, miR-621-dependent FBXO11 suppression enhanced p53 activity and increased apoptosis in breast cancer cells exposed to chemotherapeutics. Taken together, our data suggest that miR-621 enhances chemosensitivity of breast cancer cells to PTX/CBP chemotherapy by suppressing FBXO11-dependent inhibition of p53. miR-621 may serve as a predictive biomarker and a potential therapeutic target in breast cancer treatment.
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.|Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.
authors: J
authors: J
authors: Xue
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
authors: Y
authors: Y
authors: Chi
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.|Department of Oncology Surgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China.
authors: Y
authors: Y
authors: Chen
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
authors: S
authors: S
authors: Huang
authors: Institut Mérieux Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
authors: X
authors: X
authors: Ye
authors: Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.|Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
authors: J
authors: J
authors: Niu
authors: Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.|Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
authors: W
authors: W
authors: Wang
authors: Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.|Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
authors: L M
authors: LM
authors: Pfeffer
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
authors: Z-M
authors: ZM
authors: Shao
authors: Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.|Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
authors: Z-H
authors: ZH
authors: Wu
authors: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
authors: J
authors: J
authors: Wu
mesh_terms: D000328:Adult; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage; D045744:Cell Line, Tumor / Q000187:drug effects; D044783:F-Box Proteins / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008807:Mice, Inbred BALB C; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011484:Protein-Arginine N-Methyltransferases / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D044783:F-Box Proteins; C000608367:MIRN621 microRNA, human; D035683:MicroRNAs; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D016190:Carboplatin; C457579:FBXO11 protein, human; D011484:Protein-Arginine N-Methyltransferases; D017239:Paclitaxel